Page last updated: 2024-10-30

loratadine and Sneezing

loratadine has been researched along with Sneezing in 16 studies

Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.

Sneezing: The sudden, forceful, involuntary expulsion of air from the NOSE and MOUTH caused by irritation to the MUCOUS MEMBRANES of the upper RESPIRATORY TRACT.

Research Excerpts

ExcerptRelevanceReference
"Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <."9.10Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002)
" Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0."8.86Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010)
"Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P <."5.10Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. ( Harris, AG; Horak, F; Stübner, UP; Zieglmayer, R, 2002)
" Desloratadine therapy significantly reduced nasal and ocular symptom severity, itching and wheals, and sleep and activity disruption (p < 0."4.86Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. ( Bachert, C; Maurer, M, 2010)
" and intracerebroventricular pentobarbital-induced sedation and alcohol-induced ataxia models."3.76Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H. ( Bagad, AS; Bahekar, PC; Chidrewar, GU; Mandhane, SN; Mehetre, SV; Pawar, CA; Rajamannar, T; Rao, CT; Shah, JH, 2010)
"Sneezing and nasal scratching after challenges were significantly ameliorated in the Shu-Bi-Lin-treated group compared with the ovalbumin-sensitized and untreated group, but rhinorrhea volume was not reduced."3.73Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis. ( Chen, GG; Leung, PC; van Hasselt, CA; Wang, LH; Wong, YO; Woo, JK; Zhao, Y, 2006)
"Montelukast is a leukotriene receptor antagonist recently approved for the treatment of seasonal allergic rhinitis (SAR)."2.71Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. ( Arastu, R; Baidoo, CA; Faris, MA; Howland, WC; Klein, KC; Philpot, EE; Ratner, PH; Rickard, KA, 2003)
"Azelastine nasal spray is an effective treatment for patients with seasonal allergic rhinitis who do not respond to loratadine and is an alternative to switching to another oral antihistamine or to using multiple antihistamines."2.71Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. ( Berger, WE; White, MV, 2003)
"Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period."2.71The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen. ( Fujieda, S; Hyo, S; Kawada, R; Kitazawa, S; Takenaka, H, 2005)
"Treatment with loratadine resulted in a significant inhibition of the histamine-induced changes in both nasal and sinus cavities."2.69Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine. ( Baroody, FM; Blair, C; deTineo, M; Gungor, A; Haney, L; Naclerio, RM, 1999)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (18.75)18.2507
2000's10 (62.50)29.6817
2010's3 (18.75)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, J1
Yan, X1
Gai, J1
Han, J1
Zhang, H1
Luo, H1
Huang, S1
Wang, J1
Grubbe, RE1
Lumry, WR1
Anolik, R1
Mandhane, SN1
Shah, JH1
Bahekar, PC1
Mehetre, SV1
Pawar, CA1
Bagad, AS1
Chidrewar, GU1
Rao, CT1
Rajamannar, T1
Demoly, P1
Dreyfus, I1
Dhivert-Donnadieu, H1
Mesbah, K1
Bachert, C1
Maurer, M1
Ratner, PH1
Howland, WC1
Arastu, R1
Philpot, EE1
Klein, KC1
Baidoo, CA1
Faris, MA1
Rickard, KA1
Berger, WE1
White, MV1
Hyo, S1
Fujieda, S1
Kawada, R1
Kitazawa, S1
Takenaka, H1
Montaño Velázquez, BB1
Jáuregui-Renaud, K1
Bañuelos Arias, Adel C1
Ayala, JC1
Martínez, MD1
Campillo Navarrete, R1
Rosalia, IS1
Salazar, Mdel R1
Serrano, HA1
Mondragón, AO1
Perez, RL1
Zhao, Y1
van Hasselt, CA1
Woo, JK1
Chen, GG1
Wong, YO1
Wang, LH1
Leung, PC1
Buczyłko, K1
Chwała, C1
Zielińska-Bliźniewska, H1
Wagner, A1
Dzwonnik, A1
Day, JH1
Briscoe, MP1
Clark, RH1
Ellis, AK1
Gervais, P1
Baroody, FM1
Gungor, A1
deTineo, M1
Haney, L1
Blair, C1
Naclerio, RM1
Muether, PS1
Gwaltney, JM1
Horak, F1
Stübner, UP1
Zieglmayer, R1
Harris, AG1
Frølund, L1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Centre, Double-Blind, Randomised Comparison Of The Effects Of Desloratadine (Aerius®) And Placebo In The Relief Of Nasal Symptom Scores In Subjects With Seasonal Allergic Rhinitis (Sar) To Cypress Pollen[NCT00867191]Phase 4233 participants (Actual)Interventional2002-02-01Completed
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial[NCT02646020]Phase 2138 participants (Actual)Interventional2015-12-31Completed
The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis[NCT00119015]Phase 4102 participants (Actual)Interventional2005-07-31Terminated (stopped due to Difficulty in recruitment)
Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age[NCT04957927]Phase 460 participants (Anticipated)Interventional2020-12-12Recruiting
Nasal Ocular Reflexes Contribute to Eye Symptoms in Patients With Allergic Rhinitis[NCT00117832]20 participants Interventional2005-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Other Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of other symptoms, including itchy nose/eyes and post-nasal drip, twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The other symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.24
Fluticasone Propionate + Placebo-0.14

Change From Baseline in Runny Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of runny nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The runny nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.52
Fluticasone Propionate + Placebo-0.29

Change From Baseline in Sneezing Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The sneezing symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.22
Fluticasone Propionate + Placebo-0.25

Change From Baseline in Stuffy Nose Symptom Score Over 2 Week Randomized Treatment Period

"Patients recorded the severity of stuffy nose twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The stuffy nose symptom score was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 6.~The baseline symptom score used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-0.41
Fluticasone Propionate + Placebo-0.47

Change From Baseline in Total Nasal Symptom Score (TNSS) Over 2 Week Randomized Treatment Period

"Patients recorded the severity of sneezing, runny nose, stuffy nose, and other symptoms (itchy nose/eyes and post-nasal drip) twice a day on a scale from 0 to 3 (0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe). The TNSS was calculated as the sum of all scores for morning and evening recordings with a range of 0 to 24.~The baseline TNSS used in the analysis was the average of the symptom scores from the last 5 days of fluticasone propionate therapy prior to randomized treatment period.~The change from baseline for each subsequent day of treatment was then calculated for each subject. So that each subject only had one observation, the average of these changes was calculated for each subject, and this summary measure was used in the analysis comparing the two treatment groups. We report the median and full range of these average changes for each group.~A negative value indicates an improvement in symptoms." (NCT00119015)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Median)
Fluticasone Propionate + Montelukast-1.66
Fluticasone Propionate + Placebo-2.21

Reviews

1 review available for loratadine and Sneezing

ArticleYear
Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.
    Clinical drug investigation, 2010, Volume: 30, Issue:2

    Topics: Activities of Daily Living; Adult; Anti-Allergic Agents; Chronic Disease; Female; Germany; Histamine

2010

Trials

12 trials available for loratadine and Sneezing

ArticleYear
Efficacy of Bimin decoction for patients with perennial allergic rhinitis: an open-label non-inferiority randomized controlled trial.
    Trials, 2019, Dec-30, Volume: 20, Issue:1

    Topics: Adult; Anti-Allergic Agents; Drugs, Chinese Herbal; Female; Fluticasone; Humans; Loratadine; Male; M

2019
Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis.
    Journal of investigational allergology & clinical immunology, 2009, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Aged; Bronchodilator Agents; Child; Double-Blind Method; Drug Synergism; Drug The

2009
Desloratadine for the treatment of cypress pollen-induced allergic rhinitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2009, Volume: 103, Issue:3

    Topics: Adult; Antigens, Plant; Cupressus; Disease Progression; Double-Blind Method; Female; France; Histami

2009
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:5

    Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age

2003
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:5

    Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age

2003
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:5

    Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age

2003
Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 90, Issue:5

    Topics: Acetates; Administration, Intranasal; Administration, Oral; Adult; Androstadienes; Anti-Allergic Age

2003
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003, Volume: 91, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Double-Blind Method; Dru

2003
The efficacy of short-term administration of 3 antihistamines vs placebo under natural exposure to Japanese cedar pollen.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2005, Volume: 94, Issue:4

    Topics: Adult; Cetirizine; Cryptomeria; Double-Blind Method; Drug Administration Schedule; Female; Histamine

2005
Vitamin E effects on nasal symptoms and serum specific IgE levels in patients with perennial allergic rhinitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:1

    Topics: Adolescent; Adult; Allergens; Antioxidants; Child; Dietary Supplements; Double-Blind Method; Ephedri

2006
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1997, Volume: 79, Issue:2

    Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental

1997
Comparison of the response to histamine challenge of the nose and the maxillary sinus: effect of loratadine.
    Journal of applied physiology (Bethesda, Md. : 1985), 1999, Volume: 87, Issue:3

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Antagonists; Humans;

1999
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Nov-01, Volume: 33, Issue:9

    Topics: Adult; Common Cold; Histamine H1 Antagonists; Humans; Intercellular Adhesion Molecule-1; Loratadine;

2001
Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit.
    The Journal of allergy and clinical immunology, 2002, Volume: 109, Issue:6

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Loratadine

2002
Efficacy of an oral antihistamine, loratadine, as compared with a nasal steroid spray, beclomethasone dipropionate, in seasonal allergic rhinitis.
    Clinical otolaryngology and allied sciences, 1991, Volume: 16, Issue:6

    Topics: Administration, Intranasal; Administration, Oral; Adult; Aged; Beclomethasone; Cyproheptadine; Doubl

1991

Other Studies

3 other studies available for loratadine and Sneezing

ArticleYear
Characterization of anti-inflammatory properties and evidence for no sedation liability for the novel antihistamine SUN-1334H.
    International archives of allergy and immunology, 2010, Volume: 151, Issue:1

    Topics: Acetates; Alcohols; Anaphylaxis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ataxia; Cetirizin

2010
Effect of a Chinese herbal formula, Shi-Bi-Lin, on an experimental model of allergic rhinitis.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:6

    Topics: Animals; Anti-Allergic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Eosinophils; Guinea Pi

2006
[The influence of desloratadine on course of intermittens allergic rhinitis].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2005, Volume: 18, Issue:104

    Topics: Adolescent; Adult; Child; Child, Preschool; Conjunctivitis, Allergic; Disease Progression; Female; H

2005